Company’s Listing Application Approved by Nasdaq VICTORIA, BC, April 3, 2024 /PRNewswire/ – Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX: EPRX); (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize drug…